Primary Job Title Venture Partner Primary Organization 
SV Health Investors
Location Boston, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male Also Known As Daniel Burgess
Investor Type Number of Exits
Daniel Burgess joined SV Life Sciences as a Venture Partner in 2014.
Prior to joining SV, Mr. Burgess was founder, President and CEO of Rempex Pharmaceuticals, Inc. (SVLS Fund V), an antibiotic company that was sold to the Medicines Company two years after its founding in a transaction valued at up to $475 million. Previously Mr. Burgess was
President and CEO of Mpex Pharmaceuticals, Inc. (SVLS Fund IV), a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials before it was acquired by Aptalis, Inc. in 2011. Mr. Burgess has also held senior executive positions at a number of other biotechnology companies and served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion.
Mr. Burgess received an AB in Economics from Stanford University and an MBA from Harvard Business School.
